Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2021 Feb 11;41(4):1291–1305. doi: 10.1161/ATVBAHA.120.314378

Figure 2: Prothrombotic mechanisms of specific anti-cancer agents.

Figure 2:

A number of mechanisms have been identified that may contribute to the observed association between both conventional chemotherapies (blue boxes) or targeted therapies (grey boxes) and an increased risk of thrombotic events. CDK, cyclin dependent kinase; EGFR, epidermal growth factor receptor, RTKI, receptor tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.